Targeting microglial cell iron-handling in Alzheimer’s Disease
Targeting microglial cell iron-handling in Alzheimer’s Disease
批准号:
10603992
负责人:
Katrina Volk
金额:
$3.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-05-01 至 2024-04-30
关键词:
AcademiaAcuteAddressAffectAgeAge MonthsAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAmyloidAmyloid beta-ProteinAnimal ModelAnxietyAttenuatedAutopsyBehaviorBehavioralBehavioral AssayBiological AssayBrainBrain DiseasesCell physiologyCellsCharacteristicsChronicClinicalCognitionCognitiveCommunicationDementiaDepositionDevelopmentDiseaseDisease ProgressionDisease associated microgliaEarly identificationExhibitsFemaleFosteringFoundationsFunctional disorderGene Expression ProfilingGeneticGoalsHomeostasisImmuneImpaired cognitionIn VitroIncidenceIndividualInflammationInflammatoryIronLearningLightLinkLiteratureMeasurementMeasuresMemoryMentorsMicrogliaModelingMotor ActivityMusNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesOnset of illnessOutcomePathologicPathologyPerformancePlayResearchResearch PersonnelRoleSLC11A2 geneSamplingSenile PlaquesShort-Term MemorySignal TransductionSpecificityStimulusTestingTrainingTransgenic AnimalsTransgenic MiceTransgenic OrganismsUniversitiesWorkage effectanimal tissuebeta amyloid pathologybrain cellcareercellular developmentcellular targetingcerebral atrophycognitive functioncollaborative environmentcytokineextracellularglial activationhuman modelimprovedin vivoinducible Creinsightintervention effectknock-downmalemouse modelneuralneurofibrillary tangle formationneuroinflammationneuron lossnovelresponseskillssupportive environmentsynergismtargeted treatmenttau Proteinstranscriptomics
中文摘要
项目摘要
阿尔茨海默病(AD)是痴呆症最常见的病因,其发病率持续上升。这
神经退行性疾病与细胞外淀粉样β蛋白(Aβ斑块)和
神经元内的tau纠缠,这有助于一系列渐进的变化,导致神经元丢失,大脑
萎缩和认知衰退。然而,并不是所有表现出AD相关改变的个体(即Aβ
斑块)发展为临床痴呆症,表明其他趋同的病理机制协同作用,帮助推动
疾病。越来越多的证据表明神经炎症和小胶质细胞的显著存在。
阿尔茨海默病患者脑内的激活。我们和其他人在这些AD中特别显示出铁负荷增强-
相关的小胶质细胞,脑内铁含量的增加与更大的Aβ斑块沉积和
加剧了认知能力的下降。有趣的是,我的初步体外研究表明,小胶质细胞
它们在AGE和A-β诱导的炎症期间的铁处理功能。这些细胞优先上调
黑色金属进口商,二价金属运输者1(DMT1)回应Aβ,允许进口高度
活性铁,如果过量可能会加重炎症。然而,许多著名的协会
体内细胞铁负荷和小胶质细胞炎症之间的关系在疾病的晚期被显示出来
人类和动物模型,目前尚不清楚小胶质细胞铁稳态的早期变化
导致下游炎症和疾病功能障碍。因此,这个项目的目标是一个关键的
阿尔茨海默病早期症状前期小胶质细胞铁转运功能的研究
小胶质细胞铁的处理和相关的炎症状态有助于疾病的进展。为了做到这一点,我
将利用一种新的转基因小鼠模型,在AD的背景下改变小胶质细胞的铁处理
老鼠线。在抑制了小胶质细胞DMT1--我们的AD小鼠模型中的关键铁输入因子--之后,我将
评估认知和记忆表现,神经炎症标志物,脑铁和Aβ斑块负荷。
行为分析、免疫组织化学方法和无偏见的基因表达分析将是
以评估操纵小胶质细胞铁处理对与AD进展相关的标志物的影响。
最终,这个项目试图解决该领域对早期小胶质细胞理解的一个关键差距
阿尔茨海默病的功能障碍。我假设在疾病进展的早期抑制小胶质细胞DMT1
将不允许过量和慢性Aβ诱导的铁进口,从而减少下游炎症
提高AD的标志物水平。除了该项目的科学目标外,还接受了
从事这项工作将支持我成为一名独立学术研究人员的长期目标
也是导师。具体地说,培训计划强调培养技术、分析和
在学术界取得成功所需的沟通技巧。跨学科、协作、
范德比尔特大学的支持性环境为该项目的成功提供了坚实的基础。
英文摘要
Project Summary
Alzheimer’s Disease (AD) is the most common cause of dementia, and its incidence continues to rise. This
neurodegenerative disease is associated with the accumulation of extracellular amyloid beta (Aβ plaques) and
intraneuronal tau tangles, which contribute to a progressive cascade of changes leading to neuronal loss, brain
atrophy, and cognitive decline. However, not all individuals who exhibit AD-associated alterations (i.e., Aβ
plaques) develop clinical dementia, suggesting other convergent pathologies that synergize to help drive the
disease. Increasing evidence demonstrates the significant presence of neuroinflammation and microglial
activation in the brains of AD patients. We and others have specifically shown enhanced iron load in these AD-
associated microglia, and increased brain iron content is associated with greater Aβ plaque deposition and
worsened cognitive decline. Interestingly, my preliminary in vitro studies suggest that microglia specifically shift
their iron-handling function in age and during Aβ-induced inflammation. These cells preferentially upregulate
the ferrous iron importer, divalent metal transporter 1 (DMT1) in response to Aβ, allowing the import of highly
reactive iron which could worsen inflammation if in excess. However, much of the prominent associations
between cellular iron load and microglial inflammation in vivo have been shown in late disease stages in
humans and animal models, and it is not known whether early alterations in microglial iron homeostasis
contribute to downstream inflammation and disease dysfunction. Thus, this project aims to target a critical
iron-handling function of microglial cells at an early pre-symptomatic stage of AD to determine how
microglial iron handling and linked inflammatory status contribute to disease progression. To do this, I
will utilize a novel transgenic mouse model with altered microglial iron-handling on the background of an AD
mouse line. Following inhibition of microglial DMT1 – the key iron importer in our AD mouse model –, I will
assess cognition and memory performance, markers of neuroinflammation, and brain iron and Aβ plaque load.
Behavioral assays, immunohistochemical approaches, and unbiased gene expression analyses will be
performed to assess the effect of manipulating microglial iron-handling on markers related to AD progression.
Ultimately, this project seeks to address a critical gap in the field’s understanding of early microglial cell
dysfunction in AD. I hypothesize that inhibiting microglial DMT1 early during the progression of disease
will disallow excessive and chronic Aβ-induced iron import, and thus reduce downstream inflammation
and improve markers of AD. In addition to the scientific goals of the project, the training received while
conducting this work will support my long-term goal of becoming an independent academic researcher
and mentor. Specifically, the training plan set forth places emphasis on fostering the technical, analytical, and
communication skills needed to achieve a successful career in academia. The interdisciplinary, collaborative,
and supportive environment at Vanderbilt University provides a strong foundation for this project to succeed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金